NEW YORK, May 17, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of QuidelOrtho Corporation f/k/a Quidel Corporation (NASDAQ: QDEL). Shareholders who purchased shares of QDEL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially fa ...

财务数据和关键指标变化 - 第一季度2024年总收入为7.11亿美元,同比下降16%,主要是由于COVID-19收入下降 [22] - 剔除COVID-19收入后,总收入同比增长6% [22] - 第一季度2024年非呼吸系统收入为5.74亿美元,同比持平,剔除去年同期的第三方合作结算收入后,同比增长4% [23] - 第一季度2024年呼吸系统收入为1.37亿美元,其中包括约5000万美元的COVID-19收入,同比下降48% [24] - 剔除政府专供的COVID-19订单,呼吸系统收入同比增长6% [25] 各条业务线数据和关键指标变化 - 实验室业务占第一季度收入的50%,同比增长约4%,剔除去年同期的第三方合作结算收入 [7] - 输血医学业务占第一季度收入的23%,同比增长约4%,主要得益于全球ORTHO VISION Swift和ORTHO VISION Max Swift仪器的安装 [8] - 急诊检测业务占第一季度收入的26%,剔除COVID-19收入后同比增长约38%,主要得益于Sofia产品在专业市场的强劲销售 [8] - 分子诊断业务占第一季度收入的1%,剔除COVID-19收入后同比增长约15% [8] 各个市场数据和关键指标变化 - 北美地区收入同比增长5% [23] - EMEA地区收入同比增长6% [23] - 中国收入同比增长12% [23] - 其他地区(包括日本、亚太和拉美)收入同比增长6% [23] 公司战略和发展方向及行业竞争 - 公司正在进行成本削减和利润恢复计划,预计将实现约1亿美元的年度成本节约 [10][11] - 新任CEO Brian Blaser表示将专注于提高客户满意度和患者护理、改善盈利能力和现金流、降低债务水平,并在高度竞争的诊断市场中保持竞争力 [17][18] - 公司正在积极推进Savanna分子诊断平台的产品线扩展,计划在未来推出呼吸系统和其他检测项目 [9] 管理层对经营环境和未来前景的评论 - 管理层表示,尽管变革管理具有挑战性,但这也是一个提升公司实力的机会 [10] - 新任CEO Brian Blaser表示对公司的未来前景感到兴奋,看好公司在诊断市场的广泛产品线和竞争实力 [16][17] - 公司预计2024年COVID-19收入将降至1.5亿美元,Savanna在2024-2025年呼吸系统季节不会有收入贡献 [33][34] 其他重要信息 - 公司在第一季度录得17亿美元的商誉减值 [29] - 公司修改了信贷协议,将最大杠杆率从4倍提高至4.25倍,以提高运营灵活性 [31][32] - 公司决定暂时中止2024年指引,以便新任CEO有机会评估业务并制定计划 [35] 问答环节重要的提问和回答 问题1 **Jack Meehan 提问** 对Savanna分子诊断平台的看法,以及对公司利润率的期望 [40][41] **Brian Blaser 回答** 认为Savanna是一个有吸引力的竞争产品,关键是要尽快扩充产品菜单,使其在市场上具有竞争力 [42][43] 公司的目标是将经营利润率提升至高20%左右 [44] 问题2 **Maggie Boeye 提问** 对公司未来COVID-19和呼吸系统业务的预期 [50][51] **Joe Busky 回答** 公司预计2024年全年COVID-19收入为1.5亿美元,对于传统呼吸系统业务,公司采用了新的预测方法,预计2024年流感检测市场规模在4000万-6000万检测的范围内 [53][55] 问题3 **Conor McNamara 提问** 对Savanna产品上市时间表的看法 [76][77] **Mike Iskra 回答** 公司对Savanna产品的上市时间表保持谨慎,但会尽快推进呼吸系统和其他检测项目的上市进度 [77][78]

业绩总结 - Q1 2024全球年同比营收增长5%，达到711亿美元[6] - 调整后的EBITDA在2024财年第一季度为132.0百万美元，较上年同期下降了46.2%[18] 用户数据 - 北美地区的收入在2024年3月31日至2023年4月2日的三个月内下降了25.5%，达到433.9亿美元，其中呼吸道产品的常态货币收入影响为-20.1%[15] - Point of Care部门在2024年3月31日至2023年4月2日的三个月内收入下降了39.4%，达到186.6亿美元，其中COVID-19收入影响为-76.8%[16] - 呼吸道产品的收入在2024年3月31日至2023年4月2日的三个月内下降了48.3%，达到137.3亿美元，COVID-19收入影响为-76.8%[16] - COVID-19相关政府订单对呼吸道产品收入的影响为-95.3%，达到6.7亿美元[17] 未来展望 - 去除政府COVID-19订单后，呼吸道收入同比增长6%[6] - 非呼吸道产品的收入在2024年3月31日至2023年4月2日的三个月内下降了1.2%，达到573.7亿美元，其中一次性第三方结算的影响为-100.0%[17]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ FORM 10-Q ____________________________________________________________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☒ EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☐ EXCHANGE ACT OF 1934 For the transition period from to C ...

Exhibit 99.1 May 8, 2024 QuidelOrtho Reports First Quarter 2024 Financial Results - Global year-over-year revenue growth of 5% as reported and 6% in constant currency, excluding COVID-19 revenue - - Cost reduction initiatives well underway, headcount reductions expected to deliver approximately $100 million in annualized savings - - Company suspends 2024 financial guidance while it assesses business under new President and Chief Executive Officer - First Quarter 2024 Results and Recent Highlights • Revenue ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number: 001-41409 QUIDELORTHO CORPORATION (Exact name of registrant as specified in its charter) De ...

Supplemental Combined Financial Measures: This presentation contains unaudited supplemental combined financial information ("Supplemental Combined Information") that gives effect to the Combinations as if Quidel and Ortho had been combined for the applicable periods. Certain Supplemental Combined Information presented is based on the historical financial statements of Quidel and Ortho with reclassification adjustments only and do not include all of the pro forma adjustments required under Regulation S-X Art ...

QuidelOrtho Corporation (NASDAQ:QDEL) Q4 2023 Earnings Conference Call February 13, 2024 5:00 PM ET Company Participants Juliet Cunningham - VP, IR Douglas Bryant - President & CEO Joseph Busky - CFO Conference Call Participants Andrew Brackmann - William Blair Alex Nowak - Craig-Hallum Casey Woodring - JPMorgan Jack Meehan - Nephron Research Conor McNamara - RBC Andrew Cooper - Raymond James Patrick Donnelly - Citi John Sourbeer - UBS Operator Welcome to the QuidelOrtho Fourth Quarter and Full Year 2023 Fi ...

QuidelOrtho Corporation (NASDAQ:QDEL) Q3 2023 Earnings Conference Call November 1, 2023 5:00 PM ET Company Participants Juliet Cunningham - VP, IR Douglas Bryant - President and CEO Joseph Busky - CFO Conference Call Participants Patrick Donnelly - Citi Alex Nowak - Craig-Hallum Jack Meehan - Nephron Research Andrew Cooper - Raymond James John Sourbeer - UBS Operator Welcome to the QuidelOrtho Third Quarter 2023 Financial Results Conference Call and Webcast. At this time, all participant lines are in a list ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ FORM 10-Q ____________________________________________________________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 1, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm ...